Levosimendan Stada

Levosimendan, the active ingredient in Levosimendan Stada, is a calcium sensitizer and inodilator presented as an intravenous solution for intravenous administration. It enhances cardiac contractility without increasing intracellular calcium and provides vasodilation, making it useful for patients experiencing acute decompensated heart failure where rapid hemodynamic support is required.

GNH USA supplies Levosimendan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide.

Levosimendan is used in the management of heart failure syndromes where contractility support is needed.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of low perfusion. Severe chronic heart failure (when conventional therapy is insufficient): provides inotropic support to stabilize hemodynamics. Low cardiac output syndrome after cardiac surgery: helps maintain systemic circulation during the postoperative period.

Levosimendan may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: marked blood pressure fall requiring intervention. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.

When using Levosimendan, clinicians should consider several safety measures.

Monitor blood pressure: watch for hypotension, especially in patients on other vasodilators. Assess cardiac rhythm: observe for arrhythmias during infusion. Evaluate renal function: adjust therapy if severe impairment is present. Avoid concurrent strong CYP3A4 inhibitors: may increase plasma concentrations. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Levosimendan can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise levosimendan levels. - Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation. - Potent vasodilators (e.g., nitroglycerin): can cause severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate electrolyte shifts. - Beta‑blockers: may blunt desired inotropic response. - ACE inhibitors or ARBs: monitor blood pressure and renal function.